<DOC>
	<DOCNO>NCT01290172</DOCNO>
	<brief_summary>This study 5 day , single-center , randomize , double blind , placebo-controlled study evaluate efficacy safety Somatostatin use inflow modulator liver transplantation . Patient systemic hepatic dynamic collect record predefined time-points . To evaluate ischemia-reperfusion injury , plan perform liver biopsy two different time-points compare liver structure proteomic variation .</brief_summary>
	<brief_title>Evaluation Efficacy Safety Somatostatin Used Inflow Modulator Liver Transplantation .</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Portal</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>Ability willingness provide write informed consent Cirrhotic patient establish clinically significant portal hypertension ( CSPH ) define increase hepatic venous pressure gradient &gt; = 10 mmHg Recipients 1870 year age receive primary liver transplant brain dead donor live donor Whole liver graft partial liver graft include Patients recipient multiple solid organ transplant , previously receive organ tissue transplant may completely resolve thrombectomy HIV positive patient Patients known history portal thrombosis diagnose time transplantation may completely resolve thrombectomy . Patients include preoperative assessment without CSPH time first intraoperative measurement portal pressure Patients low portal perfusion ( = &lt; 90 ml/min*100 g LV ) measure time operation . Portal flow limit exclude eventuality , infusion , portal perfusion fall limit Patients portopulmonary hypertension Patients know cardiac arrhythmia Recipients cardiacdead donor Fulminant hepatic failure patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Liver transplant</keyword>
	<keyword>portal hypertension</keyword>
</DOC>